Comparison of the effectiveness and safety of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials

Tao-ping Chen¹, Yu-min Chen²*, Jian-bao Jiao¹, Yun-fei Wang¹, Li-gang Qian¹, Zhao Guo¹, Zheng Ma¹, Cui-yu Han¹ and Tong-huan Shi¹

Abstract

Background: This study aims to compare the effectiveness and safety of topical versus intravenous tranexamic acid (TXA) in reducing blood loss in primary total knee arthroplasty (TKA).

Methods: PubMed, Embase, the Cochrane Library, Web of Science, Chinese Biomedicine Literature (CBM), Wanfang Database and China National Knowledge Infrastructure (CNKI), and Google Scholar were searched for randomized controlled studies (RCTs) that compared topical versus intravenous TXA in terms of reducing blood loss during TKA from their inception to September 2015. This systematic review and meta-analysis was performed according to PRISMA criteria.

Results: Twelve studies reporting 12 RCTs comprising 1130 patients were included. Compared with the intravenous administration of TXA, the topical administration of TXA showed no significant differences in total blood loss (MD 2.08, 95% CI −68.43 to 72.60, P = 0.95), blood loss in drainage (MD 18.49, 95% CI −40.01 to 76.98, P = 0.54), hidden blood loss (MD 4.75, 95% CI −337.94 to 347.44, P = 0.99), need for transfusion (RR = 0.92, 95% CI 0.67 to 1.25, P = 0.58), hemoglobin (Hb) decline (MD −0.42, 95% CI −0.89 to 0.05, P = 0.08), and DVT occurrence (RR = 1.17, 95% CI 0.55 to 2.50, P = 0.68).

Conclusions: Compared with intravenous administration of TXA, topical administration TXA exhibits comparable effectiveness and safety in terms of reducing blood loss during TKA. Due to the poor quality of the included studies, more high-quality RCTs are needed to identify the optimal method and dose of TXA after TKA.

Keywords: Tranexamic acid, Total knee arthroplasty, Meta-analysis

Background

Total knee arthroplasty (TKA) is an effective treatment that helps to relieve severe pain and handicap induced by knee joint disease. However, TKA may cause significant perioperative blood loss ranging from 800 to 1800 mL, and 10 to 38% of patients need allogeneic blood transfusion [1–5]. Blood loss and subsequent blood transfusion can increase cost, and many complications, such as infection with HIV or other infectious diseases, fluid overload, and graft-versus-host disease can occur [6].

Many methods have been used to decrease blood loss during TKA, including the use of tourniquet, fibrin sealant, and tranexamic acid (TXA) [7–9]. The hemostasis effect of tourniquet in TKA is controversial. Wang et al. [10] revealed that total and intra-operative blood losses were reduced only with long-duration tourniquet use, while Zhang et al. [11] found that tourniquet release at the end of the TKA will activate local fibrinolysis and might increase blood loss. Auguilera et al. [12] reported...
that TXA can be more effective than fibrin sealant in reducing postoperative bleeding and transfusion requirement and that fibrin sealant use was not superior to routine hemostasis.

The use of TXA in primary TKA is today widely accepted, and several studies and meta-analyses have confirmed the efficacy of TXA at decreasing blood loss without increasing complications and costs [9, 13, 14]. Several clinical trials have identified that intravenous (IV) TXA is effective in reducing perioperative blood loss and the need for subsequent blood transfusions in TKA [15–17]. However, deep venous thrombosis (DVT) after the systemic administration of TXA is still a serious and fatal complication [18]. Therefore, many researchers have focused on the topical application of TXA via drain tube or intra-articular administration, and the topical application of TXA is considered an alternative effective route that entails less risk than IV after TKA [19, 20]. A previous meta-analysis has been published that only included five RCTs and one non-RCT [21]. Nevertheless, the comparative efficacy and safety of topical versus intravenous TXA often differs between studies. Thus, we performed a meta-analysis to compare the effectiveness and safety of topical versus intravenous TXA after TKA.

**Methods**

**Search strategy**

The following electronic databases were searched: PubMed, Embase, the Cochrane Library, Web of Science, Chinese Biomedicine Literature (CBM), Wanfang Database and China National Knowledge Infrastructure (CNKI), and Google Scholar were searched by two reviewers. Relevant studies comparing the topical administration of TXA and intravenous TXA for the management of blood loss during TKA were identified by two reviewers; the search was performed in August 2015. The keywords and Medical Subject heading (MeSH) terms used for the search were the following: “TXA,” “tranexamic acid” “total knee arthroplasty,” “total knee replacement”, “TKA”, “TKR”, and “Arthroplasty, Replacement, Knee”[Mesh]; the terms were connected by the Boolean operators AND or OR. The search string used in our research is presented in appendix A. Additionally, the reference lists of all identified full-text articles were reviewed to identify any initially omitted studies. There were no restrictions regarding language. Since this is a meta-analysis, no ethics committee or institutional review board approval was required.

**Eligibility criteria and study quality**

Study selection was performed according to the following inclusion criteria: (1) studies of patients undergoing primary TKA intervention; (2) with topical administration TXA and intravenous TXA as therapy to control blood loss; (3) studies assessing primary outcomes such as total blood loss, blood loss in drainage, hidden blood loss, need for transfusion, hemoglobin decline, and the rate of complications (DVT); and (4) studies designed as randomized controlled trials (RCTs). All the studies were required to be clinical trials. Trials on cadavers or artificial models were excluded. Letters, comments, editorials, and practice guidelines were also excluded.

According to the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0) [22], Review Manager, version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014) was used to describe the quality assessment.

**Data extraction**

Two reviewers independently extracted and recorded following data in a spreadsheet: (1) patient demographic data, author’s name, publication date, sample size, location of study, ratio of male and female subjects, the dose and method of TXA application (topical or intravenous), and whether TKA was unilateral or bilateral; (2) the method of anesthesia; and (3) total blood loss, blood loss in drainage, hidden blood loss, need for transfusion, hemoglobin decline and rate of complications (deep venous thrombosis (DVT)). If the data were presented as figures, the software “Getdata Graph Digitizer” was used to extract the data for meta-analysis.

**Outcome measures and statistical analysis**

The main parameters studied were total blood loss, blood loss in drainage, hidden blood loss, need for transfusion, hemoglobin decline, and rate of complications (DVT). Hidden blood loss (mL) was calculated as total blood loss minus blood loss collected from drains. The results are presented as the mean differences (MDs) with 95% confidence interval (CI) for continuous outcomes such as total blood loss and blood loss in drainage. Binary outcomes, such as the need for transfusion and the occurrence of DVT were presented as relative risk (RR) values with 95% CI. Statistical significance was set at P < 0.05. To summarize findings across the trials, the software RevMan 5.3 (The Cochrane Collaboration, Oxford, UK) was used to conduct the meta-analysis. Statistical heterogeneity was tested using the chi-squared test and the $I^2$ statistic. Chi-squared test results with $P > 0.1$ were considered suggestive of statistical heterogeneity. An $I^2$ statistic greater than 50% was considered to indicate substantial heterogeneity [23]. A fixed effect model was adopted if the $I^2$ statistic value was less than 50%. If the $I^2$ statistic value was greater than 50%, a sensitivity analysis was performed using Stata 12.0 (Stata Corp., College Station, TX, USA) to explore the effect of an individual study.
Results

Search result and quality assessment

The initial search yielded 385 potentially relevant studies; of these, no duplicate was found using Endnote Software. Based on the inclusion criteria, 374 studies were excluded after reading the titles and abstracts. Finally, 12 clinical trials involving 1130 patients were included in the meta-analysis \([24–36]\). The process for selecting the included studies is presented in Fig. 1. One study included four IV groups [30], and one report included two topical groups that differed in the dose and timing administration of TXA [32]. Differently dosed TXA groups were included in this meta-analysis. The characteristics of the included studies are shown in Table 1, and the doses and methods used to apply TXA are summarized in Table 2. In the included studies, 1130 patients were included in the meta-analysis [24–36]. The process for

| Table 1 Characteristics of included studies |
|---|
| Authors | Patients (T/I) | Age (mean year) (C/I) | Gender (F/M) | Diagnosis | Country | Type of prosthesis | Surgical protocol | Pneumatic tourniquet | Follow-up |
|---|
| Patel JN 2014 [31] | 47/42 | 42.6/49 | 23/66 | OA | USA | ns | Con-TKA | Yes | 4.6 |
| Maniar RN 2012 [30] | 40/160 | 67.4/67.45 | 42/158 | OA | India | Cemented | CAS-TKA | Yes | 3 |
| Seo JG 2013 [33] | 50/50 | 67.5/66.8 | 11/89 | OA | Korea | Cemented | CAS-TKA | Yes | 2 |
| Sarzaeen MM 2014 [32] | 100/50 | 67.8/66.9 | 20/130 | OA | Iran | Cemented | Con-TKA | Yes | – |
| Soni A 2014 [34] | 40/40 | 69.45/69.05 | 36/44 | OA | India | Cemented | Con-TKA | Yes | 1.5 |
| Tang Lian 2014 [29] | 30/30 | 66.5/67.1 | 20/40 | OA | China | ns | Con-TKA | Yes | – |
| Han WF 2014 [26] | 50/50 | ns | 20/80 | OA + RA | China | Cemented | Con-TKA | Yes | 3 months |
| Aguilera X 2015 [24] | 50/50 | 72.53/72.49 | 70/30 | OA + RA + DKD | Spain | Cemented | Con-TKA | Yes | 2 |
| Degas G 2015 [25] | 30/30 | 70/71 | 51/49 | OA | Germany | Cemented | Con-TKA | Yes | 25 days |
| Jiang Hua 2015 [28] | 33/40 | ns | 54/19 | DKD | China | ns | Con-TKA | Yes | 7 days |
| Hou ZY 2015 [36] | 20/20 | 67.36/67.02 | OA + RA | China | Uncemented | Con-TKA | Yes | 14 days |

NS not stated, T topical group, I intravenous group, OA osteoarthritis, RA rheumatoid arthritis, DKD degenerative knee disorders, Con-TKA conventional total knee arthroplasty, CAS-TKA computer-assisted total knee arthroplasty.
TKAs were performed, and the numbers of topical TXA and intravenous TXA were 529 and 601, respectively. Eight articles were in English, and four studies were in Chinese; all were published between 2013 and 2015. All participants in the 12 studies were elderly patients aged between 42 and 72.5 years who were planning to undergo TKA. Tourniquet was applied in all of the included studies, and the pressure of the tourniquet ranged from 100 to 350 mmHg. Detailed information regarding the risk of bias in the included studies is shown in Figs. 2 and 3.

**Table 2** Dose and method for topical and intravenous administration of TXA

| Author/s | Intervention | Methods of administration the tranexamic acid | Transfusion criteria | Thromboprophylaxis |
|----------|--------------|-----------------------------------------------|---------------------|---------------------|
| Gomez-Barrenna 2014 [27] | 3 g/100 mL | 15 mg/kg. 2 doses | One dose irrigated before joint closure, and the other half was administered intra-articularly after skin closure | Fifteen to 20 min before tourniquet release and 100 mL 3 h | Hb <80 g/L NS |
| Patel JN 2014 [31] | 2 g TXA/100 mL NS | 10 mg/kg * 1 dose | 2 min TXA before tourniquet release, with drain | One dose as IO | Hb b 8.0 g/dL + symptom LMWH |
| Maniar RN 2012 [30] | 3 g TXA/100 mL NS | 10 mg/kg * 1 dose 10 mg/kg * 2 doses 10 mg/kg * 2 doses 10 mg/kg * 3 doses | 5 min TXA before tourniquet release, clamp drain 2 h then fully open | One dose as IO Two doses as IOPO Two doses as POIPO Three doses at POIPO | Hb b 8.5 g/dL Hb b 10.0 g/dL + symptom |
| Seo JG 2013 [33] | 1.5 g TXA/100 mL | 1.5 g TXA/100 mL, NS | IXA while suturing, with no clamp drain | One dose at post-operative | Hb <80 g/L NS |
| Sarzaeem MM 2014 [32] | 1.5 gTXA/100 mL NS 3.0 gTXA/100 mL NS | 1.5 g TXA/100 mL, NS 1.5 g TXA: IXA injected through the drain after wound closure 3 g TXA: 5 min TXA before suturing, clamp drain 1 h then fully open | | | |
| Soni A 2014 [34] | 3 g TXA/100 mL | 10 mg/kg * 3 doses | 5 min TXA before tourniquet release, clamp drain 2 h then fully open | Three doses as POIPO | Hb b 8.0 g/dL LMWH |
| Tang Lian 2014 [29] | 500 mg/5 mL | 10 mg/5 mL | Intra-articular injection after suction without drain | Intravenous 15 min before tourniquet release | Hb <90 g/L LMWH |
| Han Wenfeng 2014 [26] | 1 g/50 mL | 15 mg/kg, maximum 1.2 g | Spray the TXA before suction and clamp drain for 30 min then fully open | Induction of general anesthesia | Hb <70 g/L LMWH |
| Aguilera X 2015 [24] | 1 g/10 mL | 1 g * 2 doses | The TXA was applied by syringe spray and drain was kept closed during the first hour and removed 24 h after surgery | Patients in the control group received a slow IV infusion | Hb <80 g/L Hb <80 g/L + symptoms between 8.5 and 9 g/dL + symptoms LMWH |
| Degas G 2015 [25] | 2 g | 15 mg/kg 1 dose | Intra-articular | Before deflation of the tourniquet | Hb <85 g/L Hb <95 g/L + symptoms 3.500 IU of tinzaparin |
| Jiang Hua 2015 [28] | 2 g/100 mL | 10 mg/kg 1 dose | Intra-articular | Before closing the wound NS | Enoxaparin and Rivaroxaban |
| Hou zhengyang 2015 [36] | 500 mg/10 mL | 10 mg/kg 1 dose | Intra-articular | Before insert the prosthesis | Hb <70 g/L Rivaroxaban |

NS not stated, Hb hemoglobin, LMWH low molecular weight heparin, IO intra-operative, IOPO intra-operative and postoperative, POIPO postoperative and intra-operative, POIPO intra-operative, and postoperative, TXA tranexamic acid

**Meta-analysis results**

**Blood loss (total blood loss, blood loss in drainage, and hidden blood loss)**

Five trials [12, 25, 27, 29, 30] reported data on topical versus intravenous administration for reducing total blood
loss after TKA. Statistical heterogeneity was found ($\chi^2 = 41.56, I^2 = 83\%$, $P < 0.00001$, Fig. 4) occurred, and a random-effects model was performed. Similarly, the topical application of TXA did not significantly decreased the blood loss in drainage after TKA (MD18.49, 95% CI –40.01 to 76.98, $P = 0.54$, Fig. 4) compared with intravenous administration. For hidden blood loss, statistical heterogeneity ($\chi^2 = 39.60, I^2 = 95\%$, $P < 0.00001$, Fig. 4) was found, and a random-effects model was performed. There was no significant difference between the topical and intravenous groups (MD 4.75, 95% CI –337.94 to 347.44, $P = 0.99$, Fig. 4).

**Need for transfusion**

Fifteen studies [24–27, 29–34, 36] mentioned a need for transfusion in 1206 enrolled knees. No significant heterogeneity ($\chi^2 = 13.20, I^2 = 2\%$, $P = 0.43$) was found. This paper uses a fixed-effects model, and no significant difference was found between topical TXA groups and intravenous TXA groups regarding the need for transfusion (RR = 0.92, 95% CI 0.67~1.25, $P = 0.58$) (Fig. 5).

**Hemoglobin decline**

No significant difference was found between the IV TXA with topical TXA groups (MD-0.42, 95% CI –0.89 to 0.05, $P = 0.08$, Fig. 6). Statistical heterogeneity ($\chi^2 = 107.72, I^2 = 94\%$, $P < 0.00001$, Fig. 6) exists, and a random-effects model was performed. To eliminate heterogeneity, a subgroup analysis was carried out for hemoglobin decline (Table 3).

**Thromboembolic complications**

Fourteen studies provided data about the rate of thromboembolic complications; the results of the meta-analysis indicate that the rate of thromboembolic complications for the intravenous group is 1.93% and that for the topical group is 1.58%; no significant difference was found between the two groups (RR = 1.17, 95% CI 0.55~2.50, $P = 0.68$, Fig. 7). No statistically heterogeneity ($\chi^2 = 5.72, I^2 = 0\%$, $P = 0.68$, Fig. 7) was found; therefore, a fixed-effects model was performed.

**Other outcomes**

Since the sample of other identified outcomes was not large enough for meta-analysis, we performed a descriptive analysis. For instance, Seo [33] found no significant difference between the range of motion (ROMs) at 2 months were 2.6°–123.3° and 2.5°–120.4° in the intravenous and intra-articular groups, and no significant difference was found in the intergroup

---

**Fig. 2** Summary of the risk of bias in each study
analysis. The ranges of motion 1 month postoperatively were 104° ± 10° (95% CI, 101° to 108°) in the topical group and 105° ± 11° (95% CI, 101° to 109°) in the intravenous group ($P = 0.612$) [27]. There were 0 and 1 cases of atrial fibrillation in the topical TXA and IV TXA groups, respectively. Saezaeeem [32] reported just one postoperative complication in the injected TXA group; this involved a patient with skin necrosis and more joint swelling than that seen for the intravenous group. One case of acute kidney

### Intraoperative plasma loss

| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference (IV, Random, 95% CI) | Mean Difference (Topical, Random, 95% CI) |
|-------------------|------|----|-------|------|----|-------|--------|--------------------------------------|------------------------------------------|
| Aguilera 2015     | 144.9 | 108.49 | 48 | 200.1 | 163.5 | 47 | 6.8% | -55.20 [-111.12, 0.72]              |                                           |
| Diga 2015        | 119.2 | 21 | 30 | 121 | 17 | 30 | 7.2% | 71.00 [81.33, 80.67]                  |                                           |
| Gomez-Barrena 2014 | 206.5 | 186.5 | 39 | 315.6 | 207.1 | 39 | 6.2% | -7.50 [-94.97, 79.97]                |                                           |
| Han 2014         | 296.7 | 23.3 | 50 | 301.6 | 23.3 | 50 | 7.2% | -4.90 [-84.03, 4.23]                 |                                           |
| Hou 2015         | 387.05 | 127.31 | 40 | 390.52 | 112.35 | 20 | 6.4% | 1.13 [-79.51, 81.77]                 |                                           |
| Jiang 2015       | 545.56 | 61.87 | 40 | 252.22 | 63.99 | 33 | 7.1% | 293.34 [264.28, 322.40]              |                                           |
| Maniar 2014 IO   | 268.0 | 108 | 40 | 244 | 142.2 | 40 | 6.8% | 24.00 [-31.34, 79.34]                |                                           |
| Maniar 2014 POIO | 201.0 | 100.9 | 40 | 244 | 142.2 | 40 | 6.8% | -43.00 [-97.03, 11.03]               |                                           |
| Maniar 2014 POIO | 198 | 103.5 | 40 | 244 | 142.2 | 40 | 6.8% | -46.00 [-100.50, 8.50]               |                                           |
| Maniar 2014 POIO | 159 | 86.4 | 40 | 244 | 142.2 | 40 | 6.8% | -85.00 [-136.56, -33.44]             |                                           |
| Patel 2014       | 558.7 | 370.3 | 42 | 630.2 | 331.6 | 46 | 5.0% | -71.50 [-218.89, 75.89]              |                                           |
| Sarzaeeem 2014.5g | 476.8 | 114.8 | 50 | 173.9 | 60.5 | 50 | 7.0% | 302.90 [266.93, 338.87]              |                                           |
| Sarzaeeem 2014.2g | 476.8 | 114.8 | 50 | 743.2 | 116.5 | 50 | 6.9% | -266.40 [-311.74, -221.06]           |                                           |
| Seo 2013         | 528 | 227 | 50 | 426 | 197 | 50 | 6.3% | 102.00 [18.69, 185.31]               |                                           |
| Soni 2014        | 409.5 | 185.82 | 30 | 386.5 | 89.08 | 30 | 6.5% | 23.00 [-50.74, 96.74]                |                                           |
| Subtotal (95% CI) | 609 | 605 | 100% | 609 | 605 | 100% | 18.49 [-49.81, 76.98]               |                                           |

Heterogeneity: $\tau^2 = 12301.44$, $\chi^2 = 864.26$, $df = 14$ ($P < 0.00001$); $I^2 = 98$

Test for overall effect: $Z = 0.62$ ($P = 0.54$)

### Subgroup analysis

| Study or Subgroup | Mean | SD | Total | Mean | SD | Total | Weight | Mean Difference (IV, Random, 95% CI) | Mean Difference (Topical, Random, 95% CI) |
|-------------------|------|----|-------|------|----|-------|--------|--------------------------------------|------------------------------------------|
| Aguilera 2015     | 685.02 | 314.08 | 48 | 851.84 | 464.71 | 47 | 33.1% | -186.62 [-326.45, -6.79]            |                                           |
| Hou 2015          | 769.02 | 317.06 | 20 | 892.79 | 363.59 | 20 | 31.4% | -123.77 [-335.19, 87.65]            |                                           |
| Jiang 2015        | 882.11 | 114.38 | 40 | 603.78 | 59.95 | 33 | 35.5% | 278.33 [227.41, 319.25]             |                                           |
| Subtotal (95% CI) | 108 | 100 | 100% | 108 | 100% | 100% | 4.75 [-337.94, 347.44]              |                                           |

Heterogeneity: $\tau^2 = 85701.54$, $\chi^2 = 39.60$, $df = 2$ ($P < 0.00001$); $I^2 = 99$

Test for overall effect: $Z = 0.03$ ($P = 0.98$)

Test for subgroup differences: $\chi^2 = 0.12$, $df = 2$ ($P = 0.94$); $I^2 = 0%$
injury was found in each of the topical and IV TXA groups [31].

Sensitivity analysis
A sensitivity analysis of blood loss in drainage was conducted, and the results indicated that none of the studies affected the stability of the final results (Fig. 8).

Discussion
The results of the current meta-analysis indicate that there were no significant differences in total blood loss, blood loss in drainage, hidden blood loss, need for transfusion, and minimal hemoglobin decline between topical TXA and IV TXA groups in primary TKA. Moreover, no significant difference was found in the rate of DVT between the two groups. Moreover, no adverse effects were reported in the included studies.

Patients undergoing TKA may suffer from large blood loss due to the large area of osteotomy and enhanced local fibrinolysis after tourniquet release [37]. Total blood loss can be 300 mL higher than that occurring with no tourniquet use. Thus, the topical administration of TXA can reduce postoperative blood loss when combined with the use of a drainage clamp. Furthermore, Jawhar et al. [38] reported that tourniquet use can induce ischemia during TKA and can result in higher proteolytic activity within vastus medialis cells, which may increase hidden blood loss. Compared with intravenous TXA administration, intra-articular TXA administration can be rapidly absorbed, maintaining a biological half-life of approximately 3 h within the joint fluid; this may be the reason why patients benefit from topical TXA administration [39]. TXA is an antifibrinolytic agent that activates plasminogen and stops bleeding without increasing plasma fibrin levels [40]. Several studies and meta-analyses have identified TXA as an efficacious and safe way to reduce blood loss in patients who undergo TKA [41–43], and numerous studies have focused on the efficacy of topical TXA administration in reaching a maximum hemostatic effect [44–46]. However, the most effective TXA regimen in primary TKA remains uncertain. A meta-analysis on outcomes was previously conducted to explore the difference between the two groups [21]. However, in their study, five RCTs and one prospective cohort study were included; moreover, they did not compare hidden blood loss between...
the two groups. The current meta-analysis included twelve studies and did compare hidden blood loss, which comprises a large proportion of total blood loss.

With regard to the need for transfusion, no significant difference was found between the two groups (RR = 0.92, 95% CI 0.67–1.25, P = 0.58); the dose of topical administration ranged from 0.5 to 3 g, and the dose of intravenous TXA administration ranged from 10 to 15 mg/kg. Three studies reported hidden blood loss for the two groups, and Aguilera [24] favors the use of topical administration to reduce hidden blood loss after TKA, whereas Hou and colleagues [47] found no difference between topical and intravenous administration. In this meta-analysis, no significant difference between topical and IV TXA administration was found. Our sensitivity analysis showed that the study of Sarzaeem [32] significantly affected the heterogeneity results. After carefully reviewing the study, the main difference between this study and the others is that TXA was administered by irrigating with 3 g of TXA and injecting with 1.5 g TXA. In addition, doses of topically administered TXA ranging from 0.5 g [48] to 3 g [27, 30, 34, 44, 49] have all proven effective and safe. Regarding blood loss in drainage, a large degree of heterogeneity was found between the two groups, and the sensitivity analysis showed that the inclusion of Sarzaeem’s study influences the final conclusion. After carefully reading the article, the topical administration of TXA was applied by irrigation.

DVT and subsequent PE are fatal complications after TKA, and it has been reported that 0.1–2% of patients will suffer from pulmonary embolism following TKA [50]. Theoretically, intravenous TXA administration may increase the risk of thrombosis since it is a synthetic antifibrinolytic agent that can prevent plasminogen activation, and fibrinolysis is delayed [51]. However, it has been ascertained that TXA does not inhibit fibrinolytic activity in the vein wall, and its effect on disrupted endothelium remains unknown [52]. The results of the current meta-analysis indicate that both topical and intravenous administration TXA are safe when used to reduce blood loss during TKA. The frequencies of DVT after intravenous and topical TXA administration are 11/571 and 9/568, respectively (RR = 1.17, 95% CI 0.55–2.50, P = 0.68). The reasons for this may be as follows: (1) the doses used during intravenous and topical administrations are appropriate and do not exceed the optimal dose; therefore, the fibrinolytic system will not be suppressed. (2) Most studies only evaluated symptomatic DVT and PE, and this will have affected the final conclusion.

This meta-analysis has the following limitations: (1) Only twelve studies were included, and the sample sizes used in each study were insufficient, which will affect the conclusions. (2) The studies administered TXA at different doses and using different methods, causing large heterogeneity. (3) The duration of follow-up in

| Table 3 Subgroup analysis for the hemoglobin drop |
|--------------------------------------------------|
| Outcome or subgroup | Studies | Effect estimate | \( \chi^2 \) | \( P(\%) \) | MD | 95% CI | P value |
|---------------------|--------|----------------|--------|---------|-----|---------|---------|
| Non-computer navigated TKR | 4 | 190.77 98 | 0.31 | -1.26,1.89 | 0.7 |
| High score RCT | 3 | 193.26 97 | 0.11 | -0.89,1.11 | 0.83 |

**Fig. 7** Forest plots comparing topical and intravenous TXA administration in terms of the occurrence of DVT. A Mantel-Haenszel fixed-effects model was used. Relative risk values are shown with 95% CI.
some studies was short; therefore, long-term follow-up is needed to measure the occurrence of DVT and PE.

Conclusions
In conclusion, this meta-analysis indicated that topical TXA administration exhibits comparable efficacy and safety to those of intravenous TXA, and both methods can decrease the need for transfusion, total blood loss, blood loss in drainage, and hidden blood loss without increasing the occurrence of DVT. Due to the poor quality of the included studies, more high-quality RCTs are needed to identify the optimal method and dose of TXA after TKA.

Abbreviations
CBM: Chinese Biomedicine Literature; CI: Confidence interval; CNKI: China National Knowledge Infrastructure; DVT: Deep venous thrombosis; IV: Intravenous; MD: Mean differences; Mesh: Medical subject heading; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCTs: Randomized controlled trials; RR: Relative risk; TKA: Total knee arthroplasty; TXA: Tranexamic acid

Acknowledgements
No funding was required for this systematic review and meta-analysis.

Availability of data and materials
We state that the data will not be shared since all raw data used are presented in the figures that are included in the article.

Authors' contributions
TPC conceived the study design. YMC, JBJ, and YFW performed the study, collected the data, and contributed to the study design. LGQ, ZG, and ZM prepared the manuscript. CYH and THS edited the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1Affiliated Hospital of Hebei University, Yuhua Dong Road, 212, Yuhua District, Baoding, Hebei Province, China. 2Hebei University, Yuhua Dong Road, 342, Yuhua District, Baoding, Hebei Province 071000, China.

Received: 1 November 2016 Accepted: 8 January 2017
Published online: 19 January 2017

References
1. Bong MR, Patel V, Chang E, Issack PS, Hebert R, Di Cesare PE. Risks associated with blood transfusion after total knee arthroplasty. J Arthroplasty. 2004;19:281–7.
2. Goodnough LT, Verbrugge D, Marcus RE. The relationship between hematoctrit, blood lost, and blood transfused in total knee replacement. Implications for postoperative blood salvage and reinfusion. Am J Knee Surg. 1995;8:83–7.
3. Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account. Knee. 2000;7:151–55.

4. Lotke PA, Farallì VJ, Orenstein EM, Ecker ML. Blood loss after total knee replacement. Effects of tourniquet release and continuous passive motion. J Bone Joint Surg Am. 1991;73:1037–40.

5. Hiippalä S, Strid L, Wennersen M, et al. Tranexamic acid (Cytokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth. 1995;74:534–7.

6. Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. Br J Anaesth. 2005;95:33–42.

7. Li ZJ, Fu X, Tian P, et al. Fibrin sealant before wound closure in total knee arthroplasty reduced blood loss: a meta-analysis. Knee Surg Sports Traumatol Arthrosk. 2015;23:2019–25.

8. Na YG, Bamne AB, Won HH, Kim TK. After early release of tourniquet in total knee arthroplasty, should it be reinflated or kept deflated? A randomized trial. Knee Surg Sports Traumatol Arthrosk. 2015.

9. Wei Z, Liu M. The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases. Transfus Med. 2015;25:151–62.

10. Wang K, Ni S, Li Z, et al. The effects of tourniquet use in total knee arthroplasty: a randomized, controlled trial. Knee Surg Sports Traumatol Arthrosk. 2016.

11. Zhang W, Liu A, Hu D, Tan Y, Al-Aidaros M, Pan Z. Effects of the timing of tourniquet release in cemented total knee arthroplasty: a systematic review and meta-analysis of randomized controlled trials. J Orthop Surg Res. 2014;9:2.

12. Aguilera X, Martinez-Zapata MJ, Bosch A, et al. Efficacy and safety of fibrin glue and tranexamic acid to prevent postoperative blood loss in total knee arthroplasty: a randomized controlled clinical trial. J Bone Joint Surg Am. 2013;95:2001–7.

13. Yue C, Pei F, Yang P, Xie J, Kang P. Effect of topical tranexamic acid in reducing bleeding and transfusions in TKA. Orthopaedics. 2015;38:315–24.

14. Wu Q, Zhang HA, Liu S, Meng T, Zhou X, Wang P. Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials. Eur J Orthop Surg Traumatol. 2015;25:525–41.

15. Fu DJ, Chen C, Guo L, Yang L. Use of intravenous tranexamic acid in total knee arthroplasty: a meta-analysis of randomized controlled trials. Chin J Traumatol. 2013;16:67–76.

16. Ho KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care. 2003;31:529–37.

17. Sabatinì L, Atzori F, Revello S, Scotti L, Debiasi F, Masse A. Intravenous use of tranexamic acid reduces postoperative blood loss in total knee arthroplasty (Chinese). Practical Pharmacy and Clinical Remedies. 2015; 481–84.

18. Hou Z-Y, Su C-Z, Pang T, et al. Primary unilateral cemented total knee arthroplasty: effect of tranexamic acid usage on blood loss (Chinese). Chinese Journal of Tissue Engineering Research. 2015;19:1329–34.

19. Jorn LP, Lindstrand A,Toksvig-Larsen S. Tourniquet release for hemorrhage increases bleeding: a randomized study of 77 knee replacements. Acta Orthop. 1999;70:65–67.

20. Jawhar A, Hermanns S, Ponelies N, Obertacke U, Roehl H. Tourniquet-induced ischaemia during total knee arthroplasty results in higher prosthetic activities within vastus medialis cells: a randomized clinical trial. Knee Surgery, Sports Traumatology, Arthroscopy. 2015; 1–9.

21. Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty (Chinese). Practical Pharmacy and Clinical Remedies. 2015; 481–84.

22. Higgins JPT GS. Cochrane handbook for systematic reviews of interventions version 5.1.0. 2011.http://handbook.cochrane.org.

23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

24. Aguilera X, Martinez-Zapata MJ, Hinarejos P, et al. Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a randomized controlled study in 240 patients. Clin Orthop Relat Res. 2012;470:2605–12.

25. Patel JN, Spanyer JM, Smith LS, Huang J, Yakkanti MR, Malkani AL. Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study. J Arthroplasty. 2014;29:1528–31.

26. Fang Z, Yan Y, Ma H, Zeng Y, Yu R, Wang J. Comparison of effects on intravenous and intra-articular cavity injection of tranexamic acid on blood loss volume in total knee arthroplasty (Chinese). China Pharmaceutilcs. 2015;44:4546.

27. Gomez-Barena E, Ortega-Andreu M, Padilla-Eguluz NG, Perez-Chrzanoska H, Figueroedo-Zalve R. Topical intra-articular compared with intravenous tranexamic acid to reduce blood loss in primary total knee replacement: a double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am. 2014;96:1937–44.

28. Yang Z-G, Chen W-P, Wu L-D. Effectiveness and safety of tranexamic acid to prevent postoperative blood loss in cemented total knee arthroplasty of the knee. J Bone Joint Surg Br Vol. 2001;83:702–05.
49. Gilbody J, Dhotar HS, Perruccio AV, Davey JR. Topical tranexamic acid reduces transfusion rates in total hip and knee arthroplasty. J Arthroplasty. 2014;29:681–84.
50. Bosque Jr J, Coleman SI, Di Cesare P. Relationship between deep vein thrombosis and pulmonary embolism following THA and TKA. Orthopedics. 2012;35:228–33; quiz 34–5.
51. Hamlin BR, DiGioia AM, Plakseychuk AY, Levison TJ. Topical versus intravenous tranexamic acid in total knee arthroplasty. J Arthroplasty. 2015; 30:384–86.
52. Astedt B, Liedholm P, Wingerup L. The effect of tranexamic acid on the fibrinolytic activity of vein walls. Ann Chir Gynaecol. 1978;67:203–5.